Shareholders' Equity (Details) - USD ($)						1 Months Ended					3 Months Ended
	Jan. 02, 2019	Jul. 02, 2018	Apr. 06, 2018	Aug. 11, 2017	May 05, 2017	Mar. 23, 2020	Jun. 28, 2019	Jul. 09, 2018	Feb. 21, 2018	Mar. 31, 2016	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 15, 2019	Aug. 15, 2019	Jul. 15, 2019	Jul. 02, 2019	May 15, 2019	Apr. 29, 2019	Dec. 31, 2018
Shareholders' Equity (Textual)
Preferred stock, shares authorized											350,000										350,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock purchase agreement with FBR, description				The Company filed a prospectus supplement for the sale of up to $4.8 million of shares of common stock pursuant to the FBR Sales Agreement, and the Company sold an aggregate of approximately $1 million of shares thereunder. On October 3, 2018, the Company filed an updated prospectus supplement with the SEC and may offer and sell shares of the Company's common stock pursuant to the FBR Sales Agreement having an aggregate offering price of up to $9.0 million, from time to time. The prospectus supplement filed on October 3, 2018, supersedes the prospectus supplement dated August 11, 2017, and no additional shares will be offered or sold pursuant to the prospectus supplement dated August 11, 2017.
Restricted common stock shares issued to vendors							78,338								10,000	5,000	25,000	8,681	50,000	8,681
Market offering price							$ 0.71								$ 0.88	$ 1.05	$ 0.98	$ 0.72	$ 0.83	$ 0.73
Subsequent Event [Member]
Shareholders' Equity (Textual)
Limits remaining under FBR ATM sales agreement						$ 900,000
FBR Capital Markets & Co. [Member]
Shareholders' Equity (Textual)
Common stock purchase agreement with FBR, description				The FBR Sales Agreement provides that FBR is entitled to compensation for its services in an amount equal to 3% of the gross proceeds from the sale of shares sold under the FBR Sale Agreement.	The shares sold pursuant to the FBR Sales Agreement have been and will be issued pursuant to General Instruction I.B.6 of Form S-3, which permits the Company to sell shelf securities in a public primary offering with a value not exceeding one-third of the average market value of the Company's voting and non-voting common equity held by non-affiliates in any 12-month period as long as the aggregate market value of the Company's outstanding voting and non-voting common equity held by non-affiliates is less than $75 million.
Issuance of common stock to vendor, shares	60,000
Fair value of share	$ 0.96
Weighted average price per share											$ 1.23	$ 1.03		$ 1.17
Issuance of common stock pursuant to Lincoln Park Equity Line, Shares											1,295,535	1,667,698		446,369
FBR Sales Agreement [Member]
Shareholders' Equity (Textual)
Weighted average price per share													$ 0.77
Issuance of common stock pursuant to Lincoln Park Equity Line, Shares													414,983
Altamont Pharmaceutical Holdings, LLC [Member]
Shareholders' Equity (Textual)
Company's common stock issued, percentage							5.00%
Lincoln Park Equity Line [Member]
Shareholders' Equity (Textual)
Issuance of common stock pursuant to Lincoln Park Equity Line, Shares			10,078						10,083
Common stock purchase agreement with Lincoln Park, description										The Company entered into a common stock purchase agreement with Lincoln Park. The Lincoln Park equity facility allows the Company to require Lincoln Park to purchase up to 10,000 shares (“Regular Purchase”) of the Company’s common stock every two business days, up to an aggregate of $12.0 million over approximately a 36-month period with such amounts increasing as the quoted stock price increases. In addition to the Regular Purchase and provided that the closing price of the common shares is not below $7.50 on the purchase date, the Company in its sole discretion may direct Lincoln Park on each purchase date to purchase on the next stock trading day (“Accelerated Purchase Date”) additional shares of Company stock up to the lesser of (i) three times the number of shares purchased following a Regular Purchase or (ii) 30% of the trading volume of shares traded on the Accelerated Purchase Date at a price equal to the lesser of the closing sale price on the Accelerated Purchase Date or 95% of the Accelerated Purchase Date’s volume weighted average price. The common stock purchase agreement with Lincoln Park expired on March 31, 2019, and any issuable amounts of common stock remaining at the expiration date were forfeited.
Warrants issued to purchase shares		3,106,796						466,019
Underwriters partially exercised over allotment		$ 7,766,990						$ 1,165,048
Warrants exercise price		$ 1.03						$ 1.03